Join our daily newsletter At The Bell to receive exclusive market insights
- Prescient Therapeutics (PTX) advanced its clinical programs during the June quarter
- The oncology company completed the second cohort for its phase 1b study of its PTX-200 therapy and is now progressing to a higher dose level
- Prescient also partnered with the Peter MacCallum Cancer Centre to advance its CAR-T therapy using the OmniCAR platform
- Prescient spent $1.14 million on operating activities and wrapped up the quarter with just under $16.1 million in cash
- Company shares are up 5.56 per cent and trading at 19 cents
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.
The clinical-stage oncology company focussed on driving multiple cancer programs for its PTX-100 and PTX-200 targeted therapies.
In April, the company successfully completed the second cohort for its phase 1b clinical study of PTX-100 and cytarabine in patients with acute myeloid leukemia (AML).
This cohort was dosed with 35 milligrams per square metre (mg/m2) and didn’t observe any safety or toxicity issues. This study is now progressing its higher dose level of 45 mg/m2.
Following the quarter, Prescient completed recruitment of patients for a higher dose level in its phase 1b basket study of PTX-100 in a mix of solid and haematological cancers.
A key milestone during the June quarter was Prescient entering a research partnering with the Peter MacCallum Cancer Centre to advance the development of its CAR-T therapy using the OmniCAR platform. Prescient will own any resulting intellectual property from this partnership.
In addition, a cell therapy enhancement program at Carina Biotech has been consolidated and is now being undertaken at Peter Mac which the company believes reflects its growing relationship with the world-renowned researcher.
Prescient spent $1.14 million on operating activities which mainly went towards admin and corporate costs, followed by research and development.
The healthcare stock ended the quarter with $16.09 million in cash.
Company shares were up 5.56 per cent and were trading at 19 cents at 11:48 am AEST.
